Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
EZN-2208 +/- Cetuximab in mCRC
NCT00931840Phase 2Unknown
- Sponsor
- Enzon Pharmaceuticals
- Start
- Jun 2009
- Primary completion
- Oct 2011
- Modality
- Polymer-based Nanoparticles, Small Molecules
- Countries
- 5
01
Overview
A Phase 2 trial of firtecan pegol in metastatic colorectal cancer (mCRC), sponsored by Enzon Pharmaceuticals. Status: unknown.
02
Drugs
firtecan pegol
03
Conditions
metastatic colorectal cancer (mCRC)
Beyond the preview
Go deeper on NCT00931840.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00931840.